Strata Critical Medical, Inc. (SRTAW)
| Market Cap | 461.16M +122.7% |
| Revenue (ttm) | 228.58M -9.1% |
| Net Income | 46.99M |
| EPS | 0.56 |
| Shares Out | 86.52M |
| PE Ratio | 9.81 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 638,916 |
| Open | 0.0026 |
| Previous Close | 0.0045 |
| Day's Range | 0.0003 - 0.0045 |
| 52-Week Range | 0.0003 - 0.3300 |
| Beta | 2.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 6, 2026 |
About SRTAW
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services. It also provides other clinical services comprising cardiac perf... [Read more]
News
AIAI Holdings Corporation Announces Appointment of Board of Directors
Directors bring a strong combination of technology, healthcare, national security, leadership experience, and financial and capital markets backgrounds AIAI Expected to Begin Trading on May 14, 2026 ...
Strata Critical Medical Slides: Investor presentation
Strata Critical Medical has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
Strata Critical Medical Announces Expiration of Warrants
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), announced that its warrants, both the Public Warrants (Nasdaq: SRTAW) and the Privat...
Strata Critical Medical price target raised to $11.50 from $11.25 at Ladenburg
Ladenburg analyst Jon Hickman raised the firm’s price target on Strata Critical Medical (SRTA) to $11.50 from $11.25 and keeps a Buy rating on the shares.
Strata Critical Medical reports Q1 EPS 3c, consensus (4c)
Reports Q1 revenue $67.38M, consensus $63.67M. “We are pleased to report Q1 results that came in ahead of our expectations, reflecting both strong execution on our growth plan and improving…
Strata Critical Medical backs FY26 revenue view $260M-$275M, consensus $269.18M
Backs FY26 adjusted EBITDA view $29M-$33M. “The underlying strength of our transformed economic model is finally shining through as we began generating operating cash flow this quarter. Our quality of...
Strata Critical Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw 87% revenue growth, strong clinical and logistics performance, and positive cash flow. Guidance for 2026 is reiterated, with continued M&A activity and industry trends supporting growth. Cash and liquidity remain robust.
Strata Critical Medical Earnings release: Q1 2026
Strata Critical Medical released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Strata Critical Medical Slides: Q1 2026
Strata Critical Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Strata Critical Medical Quarterly report: Q1 2026
Strata Critical Medical has published its Q1 2026 quarterly earnings report on May 6, 2026.
Strata Critical Medical Announces First Quarter 2026 Results
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the first quarter ended March 31, 2026. Financ...
Strata Critical Medical management to meet virtually with Lake Street
Virtual Meeting to be held on May 12 hosted by Lake Street.
Strata Acquires Ohio Valley Perfusion Associates
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced that it has completed the acquisition of Ohio Valley Perfusion Ass...
Strata Critical Medical Schedules First Quarter 2026 Earnings Conference Call
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical. (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the first quarter ended March 31, 2026 on Wednesday ...
Strata Critical Medical Transcript: 25th Annual Needham Virtual Healthcare Conference
The company leverages an asset-light, end-to-end logistics and clinical platform to drive growth in the fragmented organ transplant market, benefiting from regulatory changes and advances in perfusion technology. Its agnostic approach to devices, national footprint, and targeted acquisitions position it for continued above-market expansion.
Cathie Wood Sells Strata Critical Medical (SRTA), but Top Analysts See 120% Upside in This Penny Stock. Here’s Why
Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made one notable portfolio move on Monday, April 13. The ace hedge fund manager continued to cut exposure to Strata Critical Medical (SRTA), a hea...
Strata Critical Medical Proxy statement: Proxy filing
Strata Critical Medical filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
Strata Critical Medical Proxy statement: Proxy filing
Strata Critical Medical filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
Strata Critical Medical to Present at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the 25th Annual Needham Virtual He...
Craig-Hallum bullish on Strata Critical Medical, initiates with a Buy
As previously reported, Craig-Hallum analyst Bill Bonello initiated coverage of Strata Critical Medical (SRTA) with a Buy rating and $8 price target Over the past year, the company has executed…
Strata Critical Medical initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Bill Bonello initiated coverage of Strata Critical Medical (SRTA) with a Buy rating and $8 price target
Strata Critical Medical initiated with a Buy at B. Riley
B. Riley analyst Yuan Zhi initiated last night coverage of Strata Critical Medical (SRTA) with a Buy rating and $8 price target Strata operates one of the largest air transport…
Strata Critical Medical initiated with a Buy at B. Riley
B. Riley analyst Yuan Zhi initiated coverage of Strata Critical Medical (SRTA) with a Buy rating and $8 price target
Strata Critical Medical Earnings Call Transcript: Q4 2025
Q4 2025 saw 35% organic growth, record revenue, and margin expansion, driven by logistics and clinical integration. 2026 guidance was raised on strong volumes and new customer wins, with continued M&A and asset-light strategy supporting growth.
Strata Critical Medical Annual report: Q4 2025
Strata Critical Medical has published its Q4 2025 annual report on March 3, 2026.